Skip to main content

Cell Panel Screening

  • Fully customizable 96- and 384-well format drug library or single agent high-throughput drug screening.
  • Enzymatic cell viability assays and imaging based high content screening.
  • In vitro MISB Cancer Cell Lines and ex vivo patient derived functional tumor models.
  • Bliss matrix combinatorial drug screening.
  • Colony Forming Efficiency assays for long term treatment and drug washout screens.
  • RPPA mediated proteomic ultra-high-throughput drug screening. 200+ validated total and phospho-protein resolved readouts.
  • Genome scale functinal genomics using siRNA, CRISPR and miRNA libraries.
  • Tumor-immune cell co-culture drug screening using in vitro spheroid assays or ex vivo tumor explants.
  • Automated data processing and reporting.
  • Guaranteed rapid turnaround with competitive pricing.

Immuno-Oncology

  • Immunomodulation drug screening: activation/polarization and expansion assay for T cells, B cells, NK cells, myeloid cells (monocytes, macrophages, dendritic cells), MDSCs.
  • T‑cell states: naïve, central/effector memory, activation (CD69, CD25, CD137, FOXP3), proliferation (Ki‑67), exhaustion (PD‑1, LAG‑3, TIM‑3), cytotoxic markers (Granzyme B, Perforin).
  • Myeloid/innate phenotypes: M1/M2 polarization markers, HLA‑DR, CD11b, CD14, CD15, CD33, CD163, CD206.
  • Functional assays: cytokine production (intracellular IFN‑γ, TNF‑α), phospho‑signaling (pSTATs), proliferation assays, cytotoxicity readouts.
  • Checkpoint/target engagement: receptor occupancy, ligand expression.
  • Viability and apoptosis: Annexin V, cleaved caspase markers.

Molecular Biology

  • Bioinformatics services including data integration and signature development.
  • Access to next generation sequencing; WES, WGS, RNA and gene panels.
  • Whole proteome total- and phosphoproteomics.
  • Copy number assays and RT-qPCR.
  • Reverse-phase-protein array (RPPA) manufacturing.
  • Custom microarray manufacturing e.g., cell, protein, antibody and ECM microarrays.
  • Immunofluorescence assays, immunohistochemistry and digital pathology. 
  • Flow cytometry, western blots.
  • Cell line establishment.

Cell panel screening services

Overview


We offer rapid and cost-effective cell panel high-throughput screening services utilizing our proprietary MISB Cancer Cell Lines consisting of over 150 authenticated stable novel cancer cell lines and with the MISB Ex Vivo Tumor Models including models tested directly in context of our ongoing clinical studies. The MISB tumor models provide a powerful tool for translational cancer research and drug discovery. Key features of the MISB cell panel screening studies include:


  • Access to novel genetically profiled and STR verified unique cancer cell lines.
  • Fully customizable single agent and bliss matrix combination compound screening with pan-cancer or selected indication models.
  • Insightful and validated assay design support with stringent quality control and detailed reporting of the study results.
  • Therapeutic fingerprinting against a database of hundreds of reference cancer therapeutics including all standard of care and the latest novel experimental therapies.

Figure: Therapeutic fingerprinting of novel compounds against standard of care and novel cancer therapies.

Phenotypic high-throughput screening

With phenotypic imaging cytometry-powered drug and functional genetic screening it is possible to interrogate cellular responses at single cell resolution in comprehensive biology rich and integrated ways. Benefit from our 20-years´ experience in HTS dating back all the way to the era of invention of RNAi.


Our phenotypic HTS service options include
  • Proprietary MISB Cell Line Collection models (focused or pan-cancer selection of models)
  • Cost effective 384-well format screening with customer defined dosing, schedule and readout
  • Imaging cytometry for viability, cell death and cell cycle analysis (e.g., +/- EdU incorporation)
  • Immunofluorescent readouts for DNA damage (e.g., yH2Ax, 53BP1, RPA32, RAD51 foci etc.)
  • Custom assays with immunofluorescent readouts for e.g., cell differentiation with lineage markers (cytokeratins and other differentiation markers)
  • Access to a library of over 2500 FDA approved or experimental compounds including all available standard of care anti cancer therapeutics
  • Genome-wide arrayed siRNA and pooled CRISPR library. Custom siRNA libraries for transcription factors, membrane proteins, epigenetic enzymes, DNA repair, kinases/phosphatases and cherry picked libraries
  • Discovery library of 10 000+ diverse small molecules

Figure:  Application of imaging cytometry based phenotypic drug screening to assess MoA and to build biological insights to novel cancer therapies.

Want more information?